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ABSTRACT  33 
 34 
Term born infants are predisposed to human rhinovirus (HRV) lower respiratory 35 
tract infections (LRTI) by reduced neonatal lung function and genetic 36 
susceptibility.  Our aim was to investigate whether prematurely born infants 37 
were similarly predisposed to HRV LRTIs or any other viral LRTIs. Infants 38 
born less than 36 weeks of gestational age were recruited. Prior to 39 
neonatal/maternity unit discharge, lung function (functional residual capacity by 40 
helium gas dilution and multiple breath washout, lung clearance index and 41 
compliance (Crs) and resistance (Rrs) of the respiratory system) was assessed and 42 
DNA samples assessed for eight single nucleotide polymorphisms (SNPs) in 43 
seven genes: ADAM33, IL10, MMP16 NFκB1A,SFTPC, VDR and NOS2A.  44 
Infants were prospectively followed until one year corrected age.  45 
Nasopharyngeal aspirates (NPAs) were sent whenever an infant developed a 46 
LRTI and tested for 13 viruses.  One hundred and thirty-nine infants were 47 
included in the analysis.  Infants who developed HRV LRTIs had reduced Crs 48 
(1.6 versus 1.2 mL/cmH2O/kg, p=0.044) at 36 weeks postmenstrual age.  A SNP 49 
in the gene coding for the vitamin D receptor was associated with the 50 
development of HRV LRTIs and any viral LRTIs (p=0.02) . 51 
Conclusion Prematurely born infants may have both a functional and genetic 52 
predisposition to HRV LRTIs. 53 
 54 
Key words:  human rhinovirus; single nucleotide polymorphisms; compliance 55 
and resistance of the respiratory system; functional residual capacity 56 
57 
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List of abbreviations 58 
 59 
BPD  Bronchopulmonary dysplasia 60 
Crs  Compliance of the respiratory system 61 
FRCHE  Functional residual capacity (by helium gas)  62 
HRV  Rhinovirus  63 
LCI  Lung clearance index 64 
LRTI  Lower respiratory tract infection 65 
NPA  Nasopharyngeal aspirates  66 
PCR  Polymerase chain reaction 67 
PMA  Postmenstrual age 68 
Rrs  Resistance of the respiratory system  69 
RSV  Respiratory syncytial virus 70 
SNP  Single nucleotide polymorphisms  71 
VDR  Vitamin D receptor 72 
73 
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AUTHORS SUMMARY  74 
 75 
What is known  76 
• Term born infants are predisposed to rhinovirus lower respiratory tract 77 
(HRV LRTIs) infection by reduced neonatal lung function. 78 
• Term born infants requiring hospitalisation due to HRV bronchiolitis were 79 
more likely to have single nucleotide polymorphism (SNP) in the IL-10 80 
gene.  81 
 82 
What is new 83 
• Prematurely born infants who developed a HRV LRTI had lower Crs before 84 
maternity unit discharge.  85 
• A SNP in the gene coding for the vitamin D receptor was associated with 86 
the development of HRV LRTIs and overall respiratory viral LRTIs in 87 
prematurely born infants.  88 
89 
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INTRODUCTION 90 
 91 
Human rhinoviruses (HRV) are the most common cause of respiratory tract 92 
infection in infants, with almost all infants developing at least one HRV 93 
infection in the first year after birth [14, 23]. Both term and prematurely born 94 
infants are susceptible to developing LRTIs caused by HRV [3, 11, 13, 21,24].  95 
Some term born infants may be predisposed to wheezy HRV LRTIs by reduced 96 
neonatal lung function [22].  The adjusted risk of developing a wheezy HRV 97 
LRTI in the first year of life was 1.8 times higher for each standard deviation 98 
increase of airway resistance (Rrs) measured at two months of age [22]. In 99 
addition, some term born infants may be genetically predisposed to HRV 100 
infection.  Infants developing HRV bronchiolitis requiring hospitalisation at less 101 
than six months of age were more likely to have a single nucleotide 102 
polymorphism (SNP) in the IL-10 gene compared to unselected blood donors 103 
[9].  Other SNPs in genes coding for IL-18, TLR4 and IFN- did not confer 104 
susceptibility to hospitalisation for HRV infection [9].  The aim of this study 105 
was to determine whether prematurely born infants were functionally and 106 
genetically predisposed to HRV LRTIs.  An additional aim was to determine 107 
whether prematurely born infants were functionally and genetically predisposed 108 
overall to respiratory viral LRTIs.  109 
 110 
 111 
 112 
 113 
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MATERIALS AND METHODS 114 
 115 
Analysis was undertaken of the results of infants entered into a study 116 
investigating the risk factors for viral LRTIs in prematurely born infants [7].   117 
Infants were eligible for recruitment into the study if they were born prior to the 118 
onset of the RSV season (1st October to 31st March in the UK) in 2008 or 2009 119 
and were born at less than 36 weeks of completed gestation.  Ethical approval 120 
was obtained from King’s College Hospital NHS Foundation Trust Research 121 
Ethics Committee.   122 
 123 
Prior to neonatal/maternity unit discharge either blood or buccal swabs were 124 
obtained from infants and stored at -20oC until tested.  The samples were then 125 
sent on dry ice to the National Institute for Public Health and the Environment 126 
(RIVM) in Bilthoven, The Netherlands for testing.  DNA was isolated from the 127 
blood samples or buccal swabs and then stored at -20oC at the RIVM until 128 
analysed [6]. Eight single nucleotide polymorphisms (SNPs) were chosen to be 129 
tested.  The chosen SNPs had previously been associated with HRV infection in 130 
term born infants less than six months old [9]. Nuclear factor-κ-B activity has 131 
been associated with steroid resistant airway epithelium in HRV infection in 132 
vitro and thus the SNP NFκB1A rs2233409 was also included [15].  In addition, 133 
we have studied SNPs associated with reduced lung function in previously 134 
healthy children at three and five years of age [20], RSV infection in 135 
prematurely born infants [19], prematurity [10] or bronchopulmonary dysplasia 136 
(BPD) [8].  We also included SNPs associated with RSV infection in 137 
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prematurely born infants as they may  be associated with other viral causes of 138 
bronchiolitis (i.e. HRV) in prematurely born infants.  139 
 140 
The extracted DNA samples were diluted with TE Buffer to 7 ng/µL and sent to 141 
KBioscience (Herts, UK) for genotyping.  Six SNPs (ADAM33 rs2787094, 142 
IL10 rs1800872, MMP16 rs2664349, MMP16 rs2664352, NFκB1A rs2233409 143 
and SFTPC rs1124) were tested at KBioscience with the KASPar technology 144 
and two further SNPs (vitamin D receptor [VDR rs10735810] and nitric oxide 145 
synthase 2A [NOS2A rs1060826]) were tested at the RIVM in the Netherlands.  146 
Genotyping of VDR rs10735810 was performed by a custom TaqMan SNP 147 
genotyping assay (Applied Biosystems, Carlsbad, USA) and genotyping of 148 
NOS2A rs1060826 was performed by using TaqMan SNP genotyping assay 149 
C_9458082_10. Genotyping of both SNPs tested at the RIVM was carried out 150 
on a 7500 Fast Real-Time PCR system (Applied Biosystems) as previously 151 
described [6]. The genotype distributions of the eight SNPs were in Hardy-152 
Weinberg equilibrium [6]. 153 
 154 
Lung function was assessed at 36 weeks postmenstrual age (PMA) whilst infants 155 
were still inpatients on the neonatal or maternity unit.  Infants were not sedated 156 
or ventilated during lung function testing.  Lung volume was assessed by 157 
measurement of functional residual capacity (FRCHe), using a commercially 158 
available helium gas dilution system (EBS 2615, Equilibrated Bio Systems, 159 
New York) as previously described [5].  Lung volume was also assessed by the 160 
measurement of FRC (FBCMBW) using the commercially available open circuit 161 
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multiple breath wash-in/out system (Exhalyzer D, Ecomedics, Duernten, 162 
Switzerland) and using sulphur hexafluoride as a tracer gas as previously 163 
described [6].  The MBW technique also measures ventilation inhomogeneity 164 
(VI), measured as lung clearance index (LCI) as previously described [6].  165 
Compliance (Crs) and resistance (Rrs) of the respiratory system were measured 166 
using the single breath occlusion technique as previously described [7].   167 
 168 
Following neonatal or maternity unit discharge, infants were followed 169 
prospectively until one year corrected age.  Whenever an infant developed an 170 
LRTI, regardless of whether the child remained at home or required 171 
hospitalisation a nasopharyngeal aspirate (NPA) was taken.  An infant was 172 
diagnosed with a viral LRTI if they had coryzal symptoms together with a 173 
respiratory examination demonstrating either a raised respiratory rate for their 174 
age, crackles or wheeze or respiratory distress (e.g. tracheal tug or intercostal or 175 
subcostal recession).  NPAs were tested for 11 viruses (rhinovirus, RSV A and 176 
B, human metapneumovirus, influenza A and B, parainfluenza 1-3, enterovirus 177 
and parechovirus) using real time reverse transcription polymerase chain 178 
reaction (PCR) and for adenovirus and bocavirus using real time PCR as 179 
previously described [5]. 180 
 181 
The neonatal notes were reviewed to document demographic and clinical data 182 
and to document the duration of the infants’ admission on the neonatal and/or 183 
maternity unit. Antenatal, perinatal and postnatal data collected included that on 184 
maternal infections, antenatal steroid use, use of surfactant, duration of 185 
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respiratory support, development of bronchopulmonary dysplasia (BPD), 186 
postnatal infant sepsis, breast/formula feeding and use of palivizumab [7]. 187 
  188 
Statistical Analysis 189 
 190 
The infants were divided into two groups depending on their HRV LRTI status.  191 
The “no LRTI group” consisted of infants who did not develop a viral LRTI 192 
throughout the study period and the “HRV LRTI group” consisted of infants 193 
who developed at least one HRV LRTI during the study period.  The infants in 194 
the HRV LRTI group may also have had other viral LRTIs.  We also undertook 195 
a subsidiary analysis of all infants who had LRTIs with NPAs positive for  196 
respiratory viruses and compared their outcomes to infants who had no LRTI.  197 
Infants who had  LRTIs but no virus was detected from the NPA were excluded 198 
from the analysis. 199 
 200 
Data were tested for normality using the Shapiro-Wilk test.  Data were analysed 201 
using either the independent T-test, the Mann-Whitney U test, the Chi-squared 202 
test or the Fisher’s exact test as appropriate. A multivariable regression model 203 
was used to examine whether lung function at 36 weeks PMA was a predictor of 204 
HRV LRTI or respiratory viral LRTIs, independent of other variables  which in 205 
the univariate analysis were significant at p<0.1 .  Statistical analysis was 206 
carried out with IBM SPSS Statistics (version 19, New York, USA).   207 
 208 
 209 
10 
 
Sample size 210 
 211 
A sample size of 28 infants in each group allowed the detection of a difference 212 
in the premorbid lung function results equivalent to one standard deviation, with 213 
90% power and two-sided 5% significance.  A previous study [2], demonstrated 214 
a significant difference in lung function (Rrs) equivalent to one standard 215 
deviation between the groups. 216 
 217 
RESULTS 218 
 219 
During the study period two hundred and fifty one infants met the eligibility 220 
criteria for recruitment into the study (Figure 1).  One hundred and thirty-nine 221 
infants were included in the overall analysis.  Their median gestational age (GA) 222 
was 34 (range 23-35) weeks and median birth weight 1904 (range 610-3610) g.  223 
Four infants received palivizumab of which one was admitted to hospital due to 224 
an RSV LRTI.  There were significant differences when comparing the  225 
demographic data of the HRV group and the no LRTI group.  The HRV group 226 
were more immature and lighter at birth, more received surfactant, had a longer 227 
duration of supplemental oxygen, developed BPD, received palivizumab, 228 
developed postnatal sepsis and had a longer duration of neonatal/maternity unit 229 
stay (Table 1).  Comparison of those infants who developed any respiratory 230 
virus LRTI compared to no LRTI is shown in Appendix Table 1. Some infants 231 
developed more than one viral LRTI or had more than one virus detected from 232 
an NPA during a HRV LRTI (Table 2).   233 
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Eight (25%) infants in the HRV LRTI group required hospitalisation (six due to 234 
a viral LRTI [two HRV]), one due to a minor head injury and one due to 235 
gastroenteritis.  Nine (12%) infants in the no LRTI group required 236 
hospitalisation (all due to non-respiratory causes).   237 
 238 
The HRV LRTI group were more immature (36 weeks versus 37 weeks PMA, 239 
p=0.031) and of lower weight (1908 versus 2113 g, p=0.007) when their lung 240 
function was measured.  The HRV LRTI group had a smaller FRCHe 241 
uncorrected for weight (p=0.004), although this was no longer significantly 242 
different after correcting for weight (p=0.13), a smaller FRCMBW uncorrected for 243 
weight (p=0.001) which remained significantly different when corrected for 244 
weight (p=0.042), a lower Crs uncorrected for weight (p=0.001) which remained 245 
significantly different when corrected for weight (p=0.005) and a higher Rrs 246 
(p=0.028) (Table 3).  Multivariate analysis revealed that after correcting for 247 
significant differences in the demographic data the only difference in lung 248 
function between the groups that remained significant was in the Crs corrected 249 
for weight (Table 3).  There were no significant differences in the lung function 250 
results of the infants who had any respiratory virus LRTI compared to those who 251 
had no LRTI after correcting for differences in their demographics (Appendix 252 
Table 2). 253 
 254 
There were no significant differences at the genotype level in any of the SNPs 255 
between the HRV LRTI and no LRTI groups (data not shown). There was a 256 
significant difference in the SNP (rs10735810) in the VDR gene at the allele 257 
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level.  Infants with the G allele were significantly more likely (OR 2.07 (95% CI 258 
[0.98-3.13], p=0.047) to develop HRV LRTIs than those with the A allele 259 
(Table 4).  Similarly there was a significant difference in the SNP in the VDR 260 
gene at the allele level between infants who did and did not develop a 261 
respiratory viral LRTI (p=0.02) (Appendix Table 3).  262 
 263 
 264 
DISCUSSION 265 
 266 
We have demonstrated that prematurely born infants who developed HRV 267 
LRTIs had reduced premorbid lung function, that is they had significantly lower 268 
Crs than those who did not develop an HRV LRTI. In addition, a SNP in the G 269 
allele of the vitamin D receptor gene was associated with an increased risk of 270 
developing HRV LRTIs and respiratory viral LRTIs overall. 271 
 272 
Term born infants have been shown to have reduced lung function prior to 273 
developing HRV LRTIs [22].  Although, in that study overall there were no 274 
significant differences in lung function between the infants who did and did not 275 
develop an HRV infection, those infants who wheezed with an HRV infection 276 
had significantly reduced lung function (Crs and Rrs) compared with those 277 
infants who had HRV infections but did not wheeze [22].  In this study, initial 278 
analysis demonstrated several differences in lung function between infants who 279 
did and did not develop an HRV LRTI.  After adjusting for differences in the 280 
demographic data, however, the only significant difference that remained was in 281 
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Crs corrected for weight.  A possible explanation is that infants with a low Crs 282 
may have less lung distensibility leading to poorer clearance of respiratory 283 
secretions.  In term born infants, a reduced Crs was associated with an increased 284 
susceptibility to hospitalisation with RSV LRTIs as well as post RSV 285 
bronchiolitis wheezing [25].  Although there were significant differences in lung 286 
function between the all virus LRTI and the no LRTI group, these disappeared 287 
after adjusting for confounding factors. 288 
 289 
Vitamin D deficiency has been associated with an increased risk of developing 290 
viral LRTIs in infants, in particular RSV LRTIs [1, 18].  In addition, SNPs in the 291 
VDR gene have been associated with severe RSV bronchiolitis and other viral 292 
LRTIs in infants [12, 17] but no previous study has investigated the role of the 293 
VDR in HRV infection.  In this study a SNP in the gene coding for VDR was 294 
associated with the development of HRV LRTIs in prematurely born infants 295 
and, in addition, in infants overall with respiratory viral LRTIs.  Vitamin D has 296 
an important role in innate immunity [4] it is thus plausible that defects in the 297 
VDR will increase an infant’s susceptibility to HRV infections.  Only one 298 
previous study [9] has investigated the genetic susceptibility of infants to HRV 299 
infection.  In that study [9], term born infants with the A allele of a SNP (at -300 
1082) in the gene coding for IL-10 were more likely to be hospitalised for HRV 301 
bronchiolitis at less than six months of age than those with the G allele.  In this 302 
study a different SNP (rs10735810) in the IL-10 gene was not associated with 303 
HRV LRTI.  The difference in those results suggest that genetic susceptibility to 304 
HRV infection is different in term and prematurely born infants. The other SNPs 305 
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tested in this study have been associated with severe RSV infection, prematurity 306 
or BPD in prematurely born infants but not HRV infection and did not appear to 307 
influence the development of HRV LRTIs, suggesting they may not have a role 308 
in prematurely born infants’ susceptibility to HRV LRTI.  We also did not find 309 
any significant association between the SNPs tested and respiratory viral 310 
infections overall.  The numbers of infants with each viral infection precluded 311 
subanalysis at that level.  312 
 313 
The current study has strengths and some weaknesses.  A large cohort of 314 
prematurely born infants from a variety of ethnic backgrounds was prospectively 315 
followed.  Lung function was assessed before neonatal or maternity unit 316 
discharge, that is prior to any of the infants being infected with any viral 317 
infection.  The wide range of ethnicities in the study may have affected the 318 
results, as genotype differences in various ethnic groups may increase the 319 
likelihood of associations occurring by chance [16]. No correction was made for 320 
multiple testing of the genetics data; it is, therefore, possible the significant 321 
differences we demonstrate with respect to VDR could be attributable to chance. 322 
Nevertheless, we demonstrate a significant relationship not only with HRV 323 
LRTIs but any respiratory viral LRTIs.  Although infants born at less than 36 324 
weeks GA were eligible for entry into the study most of the infants recruited 325 
were born moderately prematurely (median gestational age 34 weeks) and thus 326 
the results of this study may not be generalisable to all infants born extremely 327 
prematurely. 328 
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In conclusion, prematurely born infants may be predisposed to HRV LRTIs by 329 
both reduced premorbid lung function and genetic susceptibility. A SNP in the 330 
gene coding for VDR was associated with the development overall of 331 
respiratory viral LRTIs. 332 
333 
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Table 1: Demographic data 460 
Data are shown as median (range) or n (%) 461 
 No LRTI 
 
HRV LRTI 
 
P value 
N 
 
74 32  
Gestational age (weeks) 34 (25-35) 33 (23-35) 0.03 
Birth weight (g) 2070 (895-3610) 1558 (610-2546) <0.001 
Males 49 (53%) 14 (44%) 0.53 
Ethnicity:    
Caucasian 23 (31%) 8 (25%) 0.53 
Black African 17 (23%) 9 (28%) 0.57 
Black Caribbean 15 (20%) 6 (19%) 0.75 
Asian 3 (4%) 2 (6%) 0.62 
Hispanic 1 (1%) 2 (6%) 0.16 
Mixed ethnicity 15 (21%) 5 (16%) 0.49 
Antenatal smoking 11 (15%) 6 (19%) 0.78 
Antenatal steroids 42 (57%) 24 (75%) 0.09 
Maternal sepsis 14 (19%) 4 (13%) 0.58 
Surfactant 11 (15%) 13 (41%) 0.006 
Duration of ventilation 
(days) 
0 (0-82) 1 (0-103) 0.10 
Duration of supplemental 
oxygen (days) 
0 (0-118) 1.5 (0-458) 0.041 
Bronchopulmonary 
dysplasia  
4 (5%) 8 (25%) 0.006 
Breastfed 62 (84%) 23 (72%) 0.19 
Postnatal sepsis 20 (27%) 17 (53%) 0.014 
Parental atopy 52 (70%) 20 (63%) 0.50 
Number of siblings 0 (0-5) 0 (0-5) 0.64 
Palivizumab 0 (0%) 4 (13%) 0.007 
Neonatal/maternity unit 
stay (days) 
16 (2-118) 28 (5-276) 0.003 
462 
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Table 2: Number of viruses detected by real-time PCR in the HRV LRTI group 463 
Data shown are the number of times a virus was detected. Some infants had 464 
more than one viral LRTI. 465 
 466 
 Viruses detected 
Rhinovirus 40 
RSV A 7 
RSV B 7 
Adenovirus 11 
Human metapneumovirus 3 
Influenza A 1 
Influenza B 3 
Parainfluenza 1 3 
Parainfluenza 2 0 
Parainfluenza 3 4 
Enterovirus 14 
Parechovirus 3 
Bocavirus 4 
Dual infections 24 
Triple infections 4 
 467 
 468 
469 
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Table 3: Lung function results 470 
Data are shown as median (range). 471 
 472 
 No LRTI HRV LRTI P value* P value after 
correcting 
for 
confounding 
factors** 
N 
 
74 32   
Postmenstrual age 
(PMA) (weeks) 
36 (34-42) 37 (35-43) 0.031 N/A 
Weight (g) 2113  
(1362-3360) 
1908  
(1200-2640) 
0.007 N/A 
FRCHe (mL) 55 (30-99) 49 (10-68) 0.004 0.55 
FRCHe (mL/kg) 25 (17-34) 24 (8-35) 0.13 0.59 
FRCMBW (mL) 57 (30-91) 44 (13-64) 0.001 0.16 
FRCMBW (mL/kg) 27 (16-35) 23 (10-34) 0.042 0.10 
LCI 
 
9.8 (7.0-13.6) 10.3 (7.7-13.8) 0.066 0.60 
Crs (mL/cmH2O) 
 
3.2 (1.7-5.8) 2.5 (1.0-5.4) 0.001 0.21 
Crs (mL/cmH2O/kg) 
 
1.6 (0.7-2.3) 1.2 (0.4-2.1) 0.005 0.044 
Rrs (cmH2O/L/s) 
 
69 (48-144) 76 (49-199) 0.028 0.85 
 473 
*Univariate analysis comparing the two groups 474 
**Multivariate analysis adjusting for confounding factors  475 
0 
 
Table 4: Associations at the allele levels by HRV status 476 
Data are shown as n (%). 477 
 Association at the allele level 
Gene Allele HRV LRTI No LRTI P OR (95% CI) 
Vitamin D receptor 
(VDR) 
A 
G 
13 (22%) 
47 (78%) 
51 (36%) 
89 (64%) 
0.047 0.48 (0.22-1.03) 
2.07 (0.98-3.13) 
Nitric oxide synthase 
type 2A (NOS2A) 
T 
C 
43 (72%) 
17 (28%) 
 
97 (69%) 
43 (31%) 
 
0.87 1.12 (0.55-2.31) 
0.89 (0.43-1.82) 
A disintegrin and 
metalloprotease 33 
(ADAM33) 
C 
G 
17 (28%) 
43 (72%) 
43 (31%) 
97 (69%) 
0.87 
 
0.89 (0.43-1.82) 
1.12 (0.55-2.31) 
NFκB1A  C 
T 
50 (86%) 
8 (14%) 
108 (83%) 
22 (17%) 
0.83 1.21 (0.50-2.90) 
0.82 (0.34-1.99) 
IL10 A 
C 
19 (32%) 
41 (68%) 
45 (34%) 
87 (66%) 
0.87 0.90 (0.88-1.81) 
1.11 (0.55-2.26) 
Pulmonary 
surfactant protein C 
(SFTPC) 
A 
G 
12 (20%) 
48 (80%) 
33 (24%) 
107 (76%) 
0.71 0.81 (0.36-1.80) 
1.23 (0.56-2.78) 
Matrix 
metalloproteinase-16 
(MMP16) rs2664352 
C 
T 
31 (52%) 
29 (48%) 
69 (50%) 
69 (50%) 
0.88 1.07 (0.56-2.05) 
0.94 (0.49-1.79) 
 MMP16 rs2664349 G 
A 
39 (65%) 
21 (35%) 
86 (60%) 
52 (40%) 
0.75 1.12 (0.57-2.22) 
0.89 (0.45-1.76) 
1 
 
FIGURE LEGEND 478 
 479 
Figure 1: Flow diagram of eligibility 480 
481 
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APPENDIX  482 
 483 
 484 
Table 1: Demographic data 485 
 486 
Data are shown as median (range) or n (%) 487 
 488 
 No LRTI All virus LRTI P value 
N 74 65  
Gestational age (weeks) 34 (25-35) 33 (23-35) 0.11 
Birth weight (g) 2070 (895-3610) 2000 (1440-3154) 0.001 
Males 39 (53%) 37 (57%) 0.73 
Ethnicity:    
Caucasian 23 (31%) 14 (22%) 0.25 
Black African 17 (23%) 19 (29%) 0.44 
Black Caribbean 15 (20%) 16 (25%) 0.55 
Asian 3 (4%) 3 (5%) >0.99 
Hispanic 1 (1%) 2 (3%) 0.60 
Mixed ethnicity 15 (21%) 11 (14%) 0.67 
Antenatal smoking 11 (15%) 11 (17%) 0.82 
Antenatal steroids 42 (57%) 52 (80%) 0.004 
Maternal sepsis 14 (19%) 16 (25%) 0.54 
Surfactant 11 (15%) 20 (31%) 0.04 
Duration of ventilation 
(days) 
0 (0-82) 0.5 (0-103) 0.12 
Duration of supplemental 
oxygen (days) 
0 (0-118) 1 (0-458) 0.06 
Bronchopulmonary 
dysplasia  
4 (5%) 11 (17%) 0.052 
Breastfed 62 (84%) 58 (89%) >0.99 
Postnatal sepsis 20 (27%) 23 (35%) 0.27 
Parental atopy 52 (70%)  42 (65%) 0.59 
Number of siblings 0 (0-5) 1 (0-5) 0.78 
Palivizumab 0 (0%) 5 (8%) 0.02 
Neonatal/maternity unit 
stay (days) 
16 (2-118) 25 (3-276) 0.001 
489 
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Table 2: Lung function results 490 
 491 
Data are shown as median (range). 492 
 493 
 No LRTI All virus LRTI P value* P value after 
correcting 
for 
confounding 
factors** 
N 
 
74 65   
Postmenstrual age 
(PMA) (weeks) 
36 (34-42) 36 (34-43)  N/A 
Weight (g) 2113  
(1362-3360) 
1000 
(1440-3154) 
 N/A 
FRCHe (mL) 55 (30-99) 51 (22-99) 0.008 0.98 
FRCHe (mL/kg) 25 (17-34) 24 (14-35) 0.27 0.94 
FRCMBW (mL) 57 (30-91) 53 (16-111) 0.02 0.28 
FRCMBW (mL/kg) 27 (16-35) 26 (10-42) 0.21 0.25 
LCI 9.8 (7.0-13.6) 9.8 (6.0-14.1) 0.18 0.56 
Crs (mL/cmH2O) 3.2 (1.7-5.8) 3.1 (1.0-6.7) 0.004 0.96 
Crs (mL/cmH2O/kg) 1.6 (0.7-2.3) 1.3 (0.4-2.4) 0.018 0.55 
Rrs (cmH2O/L/s) 
 
69 (48-144) 77 (43-199) 0.03 0.50 
 494 
*Univariate analysis comparing the two groups 495 
**Multivariate analysis adjusting for confounding factors  496 
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Table 3: Associations at the allele level by HRV status 497 
 498 
Data are shown as n (%). 499 
 500 
   Association at the allele level 
Gene Allele All virus 
LRTI 
No LRTI P OR (95% CI) 
Vitamin D receptor 
(VDR) 
A 
G 
28 (23%) 
94 (77%) 
51 (36%) 
89 (64%) 
0.02 0.52 (0.30-0.90) 
1.92 (1.12-3.32) 
Nitric oxide 
synthase type 2A 
(NOS2A) 
T 
C 
88 (72%) 
34 (28%) 
97 (69%) 
43 (31%) 
 
0.68 1.15 (0.67-1.96) 
0.87 (0.51-1.49) 
 
A disintegrin and 
metalloprotease 33 
(ADAM33) 
C 
G 
41 (34%) 
81 (56%) 
43 (31%) 
97 (69%) 
>0.99 1.01 (0.59-1.77) 
0.99 (0.56-1.72) 
NFκB1A  C 
T 
99 (84%) 
19 (16%) 
108 (83%)  
22 (17%)  
0.87 1.06 (0.54-2.08) 
0.94 (0.48-1.84) 
IL10 A 
C 
42 (34%) 
80 (66%) 
45 (34%) 
87 (66%) 
>0.99 1.02 (0.60-1.71) 
0.99 (0.59-1.66) 
Pulmonary 
surfactant protein 
C (SFTPC) 
A 
G 
19 (16%) 
103 (84%) 
33 (24%) 
107 (76%) 
0.12 0.60 (0.32-1.11) 
1.67 (0.89-3.13) 
Matrix 
metalloproteinase-
16 
(MMP16) 
rs2664352 
C 
T 
61 (50%) 
61 (50%) 
69 (50%) 
69 (50%) 
>0.99 1.0 (0.61-1.62) 
1.0 (0.61-1.62) 
 MMP16 
rs2664349 
G 
A 
75 (64%) 
43 (36%) 
86 (60%) 
52 (40%) 
0.84 0.95 (0.57-1.57) 
1.05 (0.63-1.75) 
 501 
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 508 
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